Claro has built a network of partnerships with other leading, key institutions to facilitate the development of its technology in the most cost-effective and time-sensitive manner. For example, during 2008 and 2009, the Company has entered into collaboration with several major hospitals to provide clinical samples from positive blood culture bottles at no cost to Claro. This information is being used to demonstrate the clinical utility of the SpectraWave™ system. This data will also be used to set specifications for sample preparation, measurement and analysis to optimize functionality of the system in the hospital laboratory. Each of Claro’s strategic partnerships provides access to highly trained personnel and resources that have been instrumental in developing critical scientific, engineering and modeling solutions.
Program for Appropriate Technology in Health (PATH; http://www.path.org/)
PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, including the Gates Foundation and USAID, PATH helps to provide appropriate health technologies and vital strategies that change the way people think and act. In 2010, PATH selected Claro’s SpectraWave technology for developing a point of care diagnostic system for anemia and Malaria for the developing world. Through a grant from USAID, PATH is providing support for foundation funding efforts and market research and product form fit studies in Africa.
Florida Blood Services and Creative Testing Solutions (FBS; http://www.FBSBlood.org)
Florida Blood Services serves as an incubator for Claro Scientific. FBS has a significant presence in the United States and is currently the country’s third largest supplier of blood and the second largest donor testing facility. The Company leases approximately 1,100 square feet which includes Class II Biosafety laboratory facilities, a conference room, and office space. In addition to providing general overhead utilities, expertise, samples,and state-of-the-art testing facilities, partnering with FBS has provided Claro with access to blood products and testing facilities to accelerate its product development efforts.
The Technology Partnership (TTP; http://www.ttp.com/)
TTP is a UK based technology and product development company working in partnership with Claro to bring its analytical instruments to market and in creating new business opportunities from advances in related technologies. TTP will support technology selection and integration, prototype development and manufacturing scale-up.
Los Alamos National Laboratory (LANL; http://www.lanl.gov)
The Company has a long-standing relationship with LANL for the development of the technology platform. LANL has participated in the joint development of the identification technology currently licensed by Claro from USF. LANL will help advance the automated sampling systems for cells and microorganisms under a series of cooperative research and development agreements. The same hardware instrumentation will be applied to Claro’s industrial particle and process analyzers. Discussions are underway to expand this collaborative effort to include the Charles Draper Laboratory, leveraging their expertise in designing optics-based measurement systems.
University of South Florida, College of Public Health (http://health.usf.edu/VP/leadership/Milhous.htm)
Claro and USF have jointly engaged in global health research initiatives for the development of rapid methods to detect infectious diseases. Claro’s primary collaborator, Dr. Wilbur Milhous is the Associate Dean for Research at the USF College of Public Health, where he also serves as a professor of Global Health. He is an internationally recognized leader in the field of infectious diseases and translational research in neglected diseases, such as malaria. Claro has drawn on his ability to move programs from the early stages of research in the basic science lab into the hands of doctors in the trenches. In his role as associate dean for research, Dr. Milhous leads a team of more than 100 public health researchers and general faculty members and oversees the college’s multimillion dollar research and training centers.
USF sponsored the successful field deployment of the SpectraWave technology for the detection of malaria in South America. In 2009, Claro, in conjunction with USF, was awarded a Florida High Tech Corridor grant to develop a diagnostic for malaria strains. The College of Public Health is providing access to infectious disease agents and clinical samples for continued research and development. Each member of Claro’s senior scientific staff maintains a faculty academic appointment in the College of Public Health.